← Back to Search

Anti-metabolites

Single Arm for Melanoma (UPCI-07-008 Trial)

Phase 1 & 2
Waitlist Available
Led By Hussein Tawbi, MD
Research Sponsored by Hussein Tawbi
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 42 months
Awards & highlights

UPCI-07-008 Trial Summary

The combination of TMZ and DAC may effect dual modulation of DNA repair genes resulting in improved clinical response.

Eligible Conditions
  • Melanoma

UPCI-07-008 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 42 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 42 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Response Rate (ORR)
Percentage of Participants That Experienced a Dose Limiting Toxicity (DLT)
Recommended Phase 2 Dose (RP2D) of DAC + TMZ
Secondary outcome measures
1-year Overall Survival (OS) Rate
6-month Progression-free Survival (PFS) Rate
Disease Control Rate (DCR)
+2 more

UPCI-07-008 Trial Design

1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment3 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Decitabine
FDA approved
Temozolomide
FDA approved
biopsy
2002
Completed Phase 4
~8270

Find a Location

Who is running the clinical trial?

Hussein TawbiLead Sponsor
Schering-PloughIndustry Sponsor
162 Previous Clinical Trials
41,481 Total Patients Enrolled
11 Trials studying Melanoma
1,418 Patients Enrolled for Melanoma
Eisai Inc.Industry Sponsor
516 Previous Clinical Trials
158,994 Total Patients Enrolled
14 Trials studying Melanoma
1,649 Patients Enrolled for Melanoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma
Hussein Tawbi 2008. "Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00715793.
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top